SCHEMBL1785344

SCHEMBL1785344

NC(=O)c1cc(N2CCCC2)ccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
ALDH1A1 P00352 3/20 0.58
LMNA P02545 3/20 0.58
HTT P42858 2/20 0.58
HPGD P15428 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
IP6K1 Q92551 1/20 0.55
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MMP2 P08253 1/20 0.48
GFER P55789 2/20 0.47
KDM4E B2RXH2 2/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
YWHAG P61981 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1785668 0.86 MAPT (0.54) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL1786156 0.86 MAPT (0.54) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL15123245 0.85 IP6K1 (0.66) MAPTALDH1A1LMNAHPGDIP6K1
SCHEMBL1785810 0.85 MAPT (0.59) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL29151160 0.84 MAPT (0.52) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL30817600 0.84 MAPT (0.52) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL7673611 0.81 IP6K1 (0.76) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL2060966 0.80 IP6K1 (0.73) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL3343696 0.80 IP6K1 (0.55) MAPTALDH1A1LMNAHTTHPGD
SCHEMBL1787171 0.80 MAPT (0.48) MAPTALDH1A1LMNAHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPT 3413/4885ALDH1A1 2084/4885LMNA 4721/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R MAPT 4086/4885ALDH1A1 650/4885LMNA 4327/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R MAPT 4300/4885ALDH1A1 918/4885LMNA 4113/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPT 3413/4885ALDH1A1 2084/4885LMNA 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.